Teva Pharmaceutical Industries Gross Margin 2010-2024 | TEVA

Current and historical gross margin for Teva Pharmaceutical Industries (TEVA) over the last 10 years. The current gross profit margin for Teva Pharmaceutical Industries as of September 30, 2024 is %.
Teva Pharmaceutical Industries Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-09-30 $16.77B $8.36B 49.85%
2024-06-30 $16.29B $8.06B 49.50%
2024-03-31 $16.00B $7.84B 48.96%
2023-12-31 $15.85B $7.65B 48.25%
2023-09-30 $15.27B $7.00B 45.83%
2023-06-30 $15.02B $6.82B 45.40%
2023-03-31 $14.93B $6.82B 45.66%
2022-12-31 $14.93B $6.97B 46.72%
2022-09-30 $15.14B $7.25B 47.90%
2022-06-30 $15.43B $7.38B 47.80%
2022-03-31 $15.56B $7.46B 47.93%
2021-12-31 $15.88B $7.59B 47.83%
2021-09-30 $16.23B $7.59B 46.78%
2021-06-30 $16.32B $7.65B 46.87%
2021-03-31 $16.28B $7.54B 46.31%
2020-12-31 $16.66B $7.73B 46.38%
2020-09-30 $16.67B $7.64B 45.80%
2020-06-30 $16.79B $7.61B 45.35%
2020-03-31 $17.10B $7.74B 45.29%
2019-12-31 $16.89B $7.54B 44.63%
2019-09-30 $16.40B $7.55B 46.04%
2019-06-30 $16.83B $7.70B 45.73%
2019-03-31 $17.36B $7.84B 45.16%
2018-12-31 $18.27B $8.30B 45.41%
2018-09-30 $19.69B $8.60B 43.65%
2018-06-30 $20.78B $9.27B 44.60%
2018-03-31 $21.80B $10.09B 46.29%
2017-12-31 $22.39B $10.62B 47.42%
2017-09-30 $23.48B $11.73B 49.98%
2017-06-30 $23.43B $11.89B 50.74%
2017-03-31 $22.74B $11.91B 52.35%
2016-12-31 $21.90B $11.86B 54.14%
2016-09-30 $20.29B $11.32B 55.77%
2016-06-30 $19.55B $11.29B 57.72%
2016-03-31 $19.48B $11.31B 58.06%
2015-12-31 $19.65B $11.36B 57.79%
2015-09-30 $19.94B $11.40B 57.16%
2015-06-30 $20.17B $11.44B 56.69%
2015-03-31 $20.25B $11.20B 55.28%
2014-12-31 $20.27B $11.06B 54.54%
2014-09-30 $20.53B $11.06B 53.87%
2014-06-30 $20.54B $10.88B 52.99%
2014-03-31 $20.41B $10.81B 52.97%
2013-12-31 $20.31B $10.71B 52.71%
2013-09-30 $20.13B $10.60B 52.64%
2013-06-30 $20.05B $10.57B 52.72%
2013-03-31 $20.12B $10.63B 52.86%
2012-12-31 $20.32B $10.65B 52.43%
2012-09-30 $20.74B $10.75B 51.81%
2012-06-30 $20.12B $10.39B 51.67%
2012-03-31 $19.33B $9.94B 51.39%
2011-12-31 $18.31B $9.52B 51.96%
2011-09-30 $17.05B $9.10B 53.35%
2011-06-30 $16.96B $9.32B 54.95%
2011-03-31 $16.55B $9.24B 55.84%
2010-12-31 $16.12B $9.07B 56.23%
2010-09-30 $15.51B $8.70B 56.11%
2010-06-30 $14.81B $8.16B 55.12%
2010-03-31 $14.41B $7.81B 54.21%
2009-12-31 $13.90B $7.37B 53.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.395B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00